Please login to the form below

Not currently logged in
Email:
Password:

Positive results in Sanofi RA trial

Sarilumab, developed by Sanofi and Regeneron, has shown positive results for the treatment of rheumatoid arthritis in a phase IIb trial, although the drug failed to show great benefit in ankylosing spondylitis patients

Sarilumab, developed by Sanofi and Regeneron, has shown positive results in a phase IIb trial concerning the drug's safety and efficacy in treating rheumatoid arthritis, although the drug failed to show great benefit in ankylosing spondylitis (AS) patients.

According to Sanofi, the MOBILITY study, involving 306 participants, demonstrated that patients treated with sarilumab in combination with a standard RA treatment, methotrexate (MTX), achieved a significant improvement in signs and symptoms of moderate-to-severe RA compared to patients treated with MTX alone.

However, when used as a treatment for AS, significant improvement was not demonstrated when compared to placebo, although the drug was well-tolerated.

"Following these encouraging phase IIb results in rheumatoid arthritis, the companies are currently discussing the dose(s) of sarilumab to advance into the phase III portion of the MOBILITY trial," said Elias Zerhouni, president, global research & development, Sanofi.

13th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Running
A marathon and a sprint
Customer experience is a long-distance race and with pharma late out of the blocks, companies need to put their foot down if they want to compete...
5 tactics to master Market Access
Is it time to rethink your game plan? To succeed at Market Access, follow these 5 tactics:...
Finding the patient voice
How patients feel and speak about clinical trials...

Infographics